KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $19.0 million.

  • Nektar Therapeutics' Shares Outstanding (Weighted Average) rose 54.97% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 54.97%. This contributed to the annual value of $12.3 million for FY2024, which is 3.31% down from last year.
  • Nektar Therapeutics' Shares Outstanding (Weighted Average) amounted to $19.0 million in Q3 2025, which was up 53.29% from $12.4 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $19.0 million for Q3 2025, and its period low was $12.1 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $13.0 million, with a median of $12.4 million in 2025.
  • As far as peak fluctuations go, Nektar Therapeutics' Shares Outstanding (Weighted Average) fell by 3.31% in 2024, and later surged by 54.97% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $12.3 million in 2021, then climbed by 1.84% to $12.5 million in 2022, then increased by 1.50% to $12.7 million in 2023, then declined by 3.31% to $12.3 million in 2024, then skyrocketed by 54.97% to $19.0 million in 2025.
  • Its last three reported values are $19.0 million in Q3 2025, $12.4 million for Q2 2025, and $12.4 million during Q1 2025.